INTRODUCTION
Histone variants replace core histones to perform a variety of specialized functions (Kamakaka and Biggins, 2005) and, as canonical histones, are prone to posttranslational modifications (PTMs). H2A.Z is an evolutionarily conserved histone variant of the canonical histone H2A, which shares $60% identity in amino acid sequence (reviewed in Zlatanova and Thakar, 2008) . H2A.Z has been implicated in many diverse and potentially opposing functions, including regulation of gene transcription, where H2A.Z has been associated with active, poised, or inactive gene expression. The contrasting roles of H2A.Z are associated with different PTMs, including lysine acetylation, monoubiquitination, and methylation (reviewed in Sevilla and Binda, 2014) (Colino-Sanguino et al., 2016) . Acetylated H2A.Z (H2A.Zac) is associated with active transcription (Bruce et al., 2005; Halley et al., 2010; Millar et al., 2006; Valdes-Mora et al., 2012) and promotes nucleosome destabilization and an open chromatin conformation . In mammals, lysines 4, 7, and 11 (K4, K7, K11) in the H2A.Z N-terminal tail are the most frequently acetylated residues . Genome-wide studies based on H2A.Zac ChIP on-chip or ChIP-seq in different cell types and organisms have revealed that the acetylated H2A.Z forms are primarily restricted to genomic regulatory regions, such as promoters and enhancers (Bruce et al., 2005; Brunelle et al., 2015; Ku et al., 2012; Millar et al., 2006; Valdes-Mora et al., 2012) . We and others have shown that H2A.Zac is associated with aberrant gene expression in prostate (Dryhurst et al., 2012; Valdes-Mora et al., 2012) and breast cancer Dalvai et al., 2012 Dalvai et al., , 2013 . Recently, we found that increased H2A.Zac levels correlate with poor prognosis in prostate cancer patients and demonstrated a pro-oncogenic role for H2A.Zac through the ectopic activation of cancer-related enhancers . Collectively, these data suggest that inhibition of H2A.Z acetylation may be a therapeutic strategy for treating prostate cancer. However, the molecular mechanisms and key players responsible for the acetylation of H2A.Z are not fully understood.
Histone lysine acetylation is catalyzed by lysine acetyltransferases (KATs). In mammalian cells, nine nuclear KATs have been identified, from which three-Tip60, CREB binding protein (CBP), and E1A binding protein p300 (p300) -can acetylate canonical histones (Ito et al., 2000; Jeong et al., 2011) . In the budding yeast Saccharomyces cerevisiae, the lysine acetyltransferase NuA4, considered the orthologue of Tip60 (Doyon et al., 2004) , is reported to acetylate Htz1, the yeast orthologue of H2A.Z (Altaf et al., 2010; Keogh et al., 2006; Millar et al., 2006) . Indeed, studies in mammalian cells have suggested a link between H2A.Zac and the Tip60 complex in locus-specific experiments (Dalvai et al., 2012 Giaimo et al., 2018) and by immunoprecipitation of the Tip60 complex followed by KAT assays with recombinant H2A.Z (Ito et al., 2018) . However, other studies showed that H2A.Zac was independent of Tip60 inhibition at locus-specific sites Narkaj et al., 2018) and in the context of DNA repair (Semer et al., 2019) , suggesting that other KATs may also be responsible for H2A.Zac.
CBP and p300 (also known as CREBBP or KAT3A and EP300 or KAT3B, respectively) are highly homologous proteins that comprise a unique KAT family and are often referred to interchangeably. p300/CBP is a transcriptional co-activator and catalyses lysine 27 acetylation of histone H3 (H3K27ac) at promoters and enhancers (Creyghton et al., 2010; Hilton et al., 2015) . p300/CBP is a multifunctional protein that acts as both a ''writer'' and a ''reader'' of lysine acetylation through its KAT domain and bromodomain (BD), respectively (Dancy and Cole, 2015; Zeng et al., 2008) . p300/CBP is a promiscuous KAT that can acetylate all four canonical histones (Weinert et al., 2018) . However, p300/CBP's ability to acetylate and/or interact with H2A.Z has not been critically evaluated.
In this study, we have interrogated two of the most likely KAT candidates for the acetylation of H2A.Zac: Tip60 and p300/CBP. Here, we provide in vitro evidence, with peptide and recombinant nucleosome substrates, that Tip60 does not efficiently acetylate H2A.Z. In contrast, we demonstrate that p300 can acetylate H2A.Z at multiple lysine residues, both in vitro and in human cells, and H2A.Zac is enhanced by p300 BDmediated H4ac reader activity. In support of this mechanism, we find a high degree of genomic overlap between H2A.Zac and H4ac at active regulatory regions, preferentially at active promoters. However, at enhancers, we find that H2A.Zac and H4ac nucleosome occupancy is differentially associated with distinct chromatin features and the transcriptional activity of the genomic region. Overall, our findings suggest that in addition to Tip60, p300/CBP is also required for H2A.Z acetylation, providing new insights for the modulation of H2A.Zac pro-oncogenic activity in prostate cancer.
RESULTS p300 Acetylates H2A.Z In Vitro
To test whether our putative KAT candidates acetylated H2A.Z, we performed in vitro lysine acetyltransferase assays with recombinant Tip60 and p300 (Figures S1A and S1B). As substrates, we used biotinylated peptides corresponding to the first 19 amino acids of H2A.Z ( Figure 1A ) and observed acetylation rates by measuring radioactive acetyl group incorporation ( Figure 1B ). As a negative control, we used an H2A.Z peptide containing the most commonly acetylated lysines (K4, K7, and K11) Ishibashi et al., 2009) . For positive controls, known substrates for each KAT were used, including an H4 N-terminal peptide for Tip60 (Kimura and Horikoshi, 1998) and an H3 peptide flanking H3K27 for p300 (Jin et al., 2011) . Recombinant Tip60 rapidly acetylated the positive control H4 peptide. However, H2A.Z only showed a slight increase in acetylation signal compared with the negative control H2A.ZK4acK7acK11ac ( Figure 1B , upper panel and Figure S1C ). These data suggest that H2A.Z peptides are not optimal substrates for recombinant Tip60. In contrast, recombinant p300 (catalytic domain plus BD) ( Figure S1A ), which shares 82% of protein domain identity with CBP, acetylated H2A.Z peptides at a similar rate to its most appreciated histone substrate, H3K27 ( Figure 1B , bottom panel). We confirmed this activity with full-length recombinant p300 ( Figure S1D ). p300 activity toward peptide substrates of H2A.Z isoform 2 ) was similar to isoform 1 (referred herein as H2A.Z) (Figures S1E and S1F).
H2A.Z-containing nucleosomes have slightly different biophysical properties than those containing canonical H2A, including an extended acidic path on the nucleosome surface (Suto et al., 2000) , which may affect the interactions with KAT domains. To confirm our peptide results on more physiologically relevant substrates, we performed in vitro KAT assays using recombinant mononucleosome substrates (Figures 1C and 1D) . Reactions were separated by gel electrophoresis and incorporation of tritiated acetyl groups was detected using autoradiography, allowing deconvolution of which histones were acetylated. Consistent with our peptide results, recombinant Tip60 acetylated H4 in both canonical and H2A.Z-1-containing nucleosomes ( Figure 1C) ; however, no acetylation of H2A.Z was detected. Moreover, we found Tip60 autoacetylation, which positively regulates Tip60 catalytic activity (Yang et al., 2012) , suggesting that the recombinant Tip60 is functionally active. In contrast, p300 acetylated all histones in the canonical nucleosomes after 30 min of incubation ( Figure 1D ), as previously reported (Ogryzko et al., 1996; Schiltz et al., 1999) . Notably, p300 also acetylated all histones in the H2A.Z-1-and H2A.Z-2-containing nucleosomes, including both H2A.Z isoforms ( Figure 1D ). Canonical nucleosomes were a slightly better substrate than Figure 1. H2A.Z Is a Substrate for p300 In Vitro Assays (A) H2A.Z-1 N-terminal amino acid sequence for the peptides used in panel (B) . All lysines that can be acetylated are shown in red. (B) In-solution H 3 -Acetyl-CoA (AcCoA) assays measuring Tip60 (top) and p300 (bottom) activity as a function of time on the following histone peptide substrates: un-acetylated H2A.Z (peptide spans from amino acid 1-19, H2A.Z-1 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) ) and the tri-acetylated H2AZ at lysines 4, 7, and 11 (1-19) (H2A.Z-1 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) K4acK7acK11ac) were used for both Tip60 and p300 assays. As controls we used H4 (1-23) and acetylated H4 at lysines 5, 8, 12, and 16 (1-23) (H4 (1-23) K5acK8acK12acK16ac) for Tip60 and H3 (15-34) and acetylated H3 at lysine 27 peptides (15-34) (H3 (15-34) K27ac) for p300. Data points are presented as mean count per minute (cpm). Error bars represent the standard deviation (SD) from two measurements. (C) Coomassie staining (left) and H 3 fluorography (right) of recombinant canonical nucleosomes (canonical nuc) and homotypic H2A.Z-1 nucleosomes (H2A.Z-1 nuc) incubated with Tip60 in the presence or absence of H 3 -AcCoA for 12 h. White bands in the autoradiography are the overlayed molecular weight markers shown in the Coomassie staining. Representative image of two replicates. (D) H 3 fluorography (top) and Coomassie staining (bottom) of recombinant canonical nucleosomes (canonical nuc) and homotypic H2A.Z-1 and H2A.Z-2 nucleosomes (H2A.Z-1/H2A.Z-2 nuc) incubated with p300 in the presence or absence of H 3 -AcCoA for 30 min. Representative image of two replicates. (E) In-solution H 3 -AcCoA KAT assays measuring p300 activity as a function of time on nucleosome substrates, as indicated. Data points are presented as mean count per minute (cpm). Error bars represent the SD from two measurements. (F) Percentage of area under the mass spectrometry (MS) peak of unacetylated, one acetylated lysine (mono-ac), two acetylated lysines (di-ac), three acetylated lysines (tri-ac), or four acetylated lysines (tetra-ac) from H2A.Z peptides at increasing p300 incubation time points, 0, 4, 8, 16, 32, and 64 min (raw data are displayed in Figure S2 .). Data are represented as mean À/+ SD of two independent replicates. See also Figures S1 and S2.
iScience 21, 773-788, November 22, 2019 775 variant-containing nucleosomes, but no differences were found in the acetylation rates between nucleosomes containing H2A.Z-1 and H2A.Z-2 isoforms ( Figure 1E ).
Mass spectrometry data from human cells have shown that H2A.Zac is found most commonly as a tri-acetylated form, with lysines 4, 7, and 11 (K4, K7 and K11) carrying acetyl groups Ishibashi et al., 2009) . To determine whether p300 acetylates these residues, we used mass spectrometry to map acetylation sites on H2A.Z N-terminal peptide after reaction with p300 ( Figures 1F and S2A ). By four minutes, 90% of all peptides were acetylated, and unacetylated peptides were not detectable in the subsequent time points. Mono-acetylated (mono-ac) peptides were only present after 4, 8, or 16 min, and the proportion decreased by half over the time course (63.6%, 36.9%, and 17.8%, respectively). In contrast, tetra-acetylated peptides were detected (14.4% and 21.1%) at the longest time points (32 and 64 min). Tandem MS analysis showed that all lysines on the N-terminus of H2A.Z (K4, K7, K11, K13, and K15) could be acetylated by p300, but K4 and K7 were preferred ( Figure S2B ).
In summary, we provide biochemical evidence that the lysine acetyltransferase Tip60 alone is not sufficient to acetylate H2A.Z. In contrast, we show that p300 on its own rapidly acetylates both H2A.Z peptides and H2A.Z-containing nucleosomes at multiple N-terminal lysines.
Inhibition of p300 and Tip60 Decreases H2A.Zac
To determine whether p300 and Tip60 acetylate H2A.Z in cells, we used A-485, a recently developed and highly selective and potent inhibitor for p300/CBP KAT domains (Lasko et al., 2017) (Figure 2A ), as well as genetic inhibition of Tip60, p300, and CBP by siRNA in two human cancer cell lines (LNCaP and HCT116) ( Figures 2B and 2C ). We isolated chromatin fractions from all conditions and performed Western blot analysis. To test changes in H2A.Z acetylation, we used three antibodies against different H2A.Z acetylation forms: H2A.Ztri-ac (K4, K7 and K11), H2A.ZK4ac, and H2A.ZK7ac. We characterized the antibody substrate affinity by peptide microarray, as previously described (Rothbart et al., 2012a) . We found that H2A.Ztri-ac specifically recognizes the tri-acetylated form of H2A.Z; H2A.ZK4ac binds to substrates that contain H2A.Z-K4ac but does not distinguish between degrees of acetylation, whereas H2A.ZK7ac binds exclusively to mono-acetylated H2A.Z at K7 ( Figure S3 ).
Using these antibodies, we found that cells treated with A-485 had a strong and consistent dose-dependent reduction of the positive control H3K27ac between cell lines, whereas the less specific substrate, H4tetraAc, did not show a clear reduction ( Figure 2A ). Signal from the H2A.Ztri-ac antibody did not show a significant reduction in either of the cell lines, whereas H2A.ZK4ac and H2A.ZK7ac showed a clear dose-dependent decrease. At 10 mM concentration of A-485, the mono-acetylated H2A.Z antibodies showed an average reduction of 67% and 92% in LNCaP and HCT116 cells, respectively. No clear differences were detected between the reduction of H2A.ZK4ac and H2A.ZK7ac. These data suggest that inhibition of p300/CBP by A-485 preferentially reduces H2A.ZK4ac and H2A.ZK7ac mono-acetylated forms.
There are currently no selective Tip60 inhibitors commercially available. Therefore, we performed siRNA knockdown (KD) experiments to investigate the effects on H2A.Zac ( Figures 2B and 2C ). Tip60 mRNA levels were reduced by 87% and protein abundance by 80% following Tip60 KD ( Figures 2B and 2C ). H2A.Zac was significantly reduced after Tip60 KD, 58% for the triAc, 45% for K4ac, and 79% for K7ac ( Figure 2C ), as previously reported in Tip60 conditional knockout experiments (Li et al., 2019) . We found that the tetra-acetylated form of H4 was reduced by 64%, in line with our cell-free assays. We also performed siRNA experiments for the double p300/CBP KD and a triple p300/CBP/Tip60 KD. Even though the mRNA levels of p300 and CBP in the double KD were moderately decreased ($50% and 32%, respectively, Figure 2B ), the positive control H3K27ac was reduced by 92% ( Figure 2C ), suggesting the HAT inhibition was enough to detect changes in the histone acetylation profile. Interestingly, Tip60 mRNA levels increased by two-fold after p300/CBP KD but this did not translate to a significant change of Tip60 protein level ( Figure 2B ). The double p300/CBP KD reduced all H2A.Zac forms to a similar ratio as the Tip60 KD ( Figure 2C ). However, the triple KD of CBP, p300 and Tip60 showed a greater reduction of H2A.Z acetylation in comparison to the single Tip60 or p300/CBP KDs ( Figures 2B and 2C ). Interestingly, K7 acetylation was the most reduced in all KD combinations, with 97% reduction in the triple KD.
A recent resource paper mapped the p300 acetylome in mammals using quantitative mass spectrometry after genetic or chemical modulation of p300 activity (Weinert et al., 2018) . We analyzed this H2A.Z Cells were transfected with a pool of four siRNAs for Tip60 and CBP and three siRNAs for p300 (See Table S3 for siRNA sequences). The pools were then combined accordingly for the double p300/CBP KD and triple p300/CBP/Tip60 KD. mRNA expression of Tip60, p300, and CBP was measured by real-time qPCR in cells transfected with Tip60, p300, and CBP siRNAs (left). mRNA levels of all conditions were calculated relative to untargeted siRNA control (scramble). Data are represented as mean and SD (n = 2), and Student's t-test was performed to compare each condition to scramble. Densitometry quantification of each Tip60 band was normalized to the loading control H4 and relative to scramble, and it is represented as logarithmic scale. The mean relative abundance of each band and SD was plotted and Student's t-test was performed to compare each condition to scramble. *p value<0.05, **p value<0.01, ***p value<0.001. Find list of siRNA and primer sequences in Tables S3 and S4, respectively. (C) Western blot analysis of the chromatin fractions from LNCaP cells transfected with the scramble control (Scrble) Tip60 siRNA (siTIP60), p300, and CBP siRNAs (sip300/CBP) or p300, CBP, and Tip60 siRNAs (sip300/CBP/TIP60). The figure shows a representative image of at least two biological replicates (top) and densitometry quantification (bottom). Histone acetylation abundance was measured by densitometry and calculated relative to the scramble control. acetylation data and confirmed our in vitro and in-cell results ( Figure 2D ). Consistently, H2A.Z acetylation at lysines K4, K7, K11, and K13 was reduced after chemical inhibition of p300 KAT activity in both MEFs and Kasumi-1 cell lines ( Figure 2D ). The greatest effect was observed in the p300/CBP double knockout. Taken together, these data strongly support the conclusion that p300/CBP is a major KAT for H2A.Z in cells. We found that although Tip60 can modulate acetylation levels of H2A.Zac, it is not the sole KAT for H2A.Z and that p300/CBP is also essential for the acetylation of H2A.Z ( Figure 6A ).
Interaction of p300 BD with H4ac Promotes p300-mediated H2A.Z Acetylation In Vitro
Previous studies have shown that p300 BD binds H4ac, thereby acting as a reader of histone acetylation (Delvecchio et al., 2013; Nguyen et al., 2014) . Interestingly, there is high sequence homology between H4 and H2A.Z at their N-termini ( Figure S4A ), where the spacing of the lysines follow the same KAc(X) 2-3 KAc pattern, in which X represents any amino acid, which is reported to have the strongest p300 BD binding (Delvecchio et al., 2013) . We questioned whether the p300 BD was also capable of reading H2A.Zac. Using histone peptide arrays printed with approximately 260 uniquely modified histone peptides , including major single and combinatorial acetylations on all four core histones and the variant H2A.Z (see Table S1 ), we revealed that p300 BD binds exclusively to H4-acetylated peptides (Figures 3A and S4B) . No binding was measured for acetylated H2A.Z or any other acetylated histone peptide in the library.
A feedforward mechanism of p300-dependent H3K27 acetylation through BD recruitment to H4ac has been previously proposed (Nguyen et al., 2014) . Indeed, in our in vitro KAT assays, the rate of p300 acetylation on nucleosomes pre-installed with H4ac was faster than unmodified nucleosomes ( Figure 3B ). Thus, we hypothesized that the p300 BD interaction with H4ac may also enhance H2A.Z acetylation. To test this hypothesis, we first performed a time course radioactive KAT assay with recombinant p300 and H2A.Z-containing nucleosome substrates ( Figure 3C ). As expected, we observed time-dependent acetylation on all nucleosomal histones. Notably, H2A.Z acetylation trailed H4 acetylation in this time course.
We next used the p300 BD inhibitor, CBP30 (Conery et al., 2016; Hammitzsch et al., 2015) , to further question whether p300 BD activity impacts H2A.Z acetylation. Using the same peptide array approach, we validated that CBP30 completely blocks the p300 BD from binding to H4-acetylated peptides (Figures 3D, S4C, and S4D). We performed in vitro KAT assays in the presence and absence of CBP30 using recombinant canonical, H2A.Z-containing, and H4ac-containing nucleosomes. Inhibition of the p300 BD resulted in decreased acetylation of all histones, including histone H2A.Z ( Figure 3E ). To further validate that BD recruitment enhances p300-mediated H2A.Z acetylation, we treated HCT116 cells with CBP30 for 24 h using a concentration range (1-10uM), recommended by Conery et al., 2016 ( Figure 3F ). We observed a reduction in H3K27ac levels, as previously reported (Raisner et al., 2018) . Notably, there was also a decrease in H2A.Zac levels, where H2A.ZK7ac showed a striking reduction of up to 90%. Taken together, these data suggest that acetylation of H2A.Z by p300 is enhanced upon recruitment to H4-acetylated nucleosomes via the p300 BD.
H2A.Zac and H4K5ac Co-occur at Promoter Regions
We next sought to determine whether H2A.Zac-and H4ac-marked nucleosomes co-exist in the chromatin. To address this, we determined the genomic distribution of both marks using publicly available ChIP-seq data for H2A.Zac and H4K5ac in LNCaP cells (Table S2 ). The specificity of both antibodies was characterized with histone peptide arrays (Rothbart et al., 2012a; (Figure S3A for H2A.Ztri-ac and http://www.histoneantibodies.com/ for H4K5ac). As previously reported (Rothbart et al., 2012b (Rothbart et al., , 2015 , the H4K5ac antibody bound preferentially to H4 peptides that also have acetylation at other sites forming Log2 SILAC normalized ratios for each detectable acetylation site of H2A.Z-1 and H2A.Z-2 isoforms were plotted. SILAC normalized ratios were calculated as explained in Weinert et al. (2018) . The peptides containing K4ac are identical between isoforms, and therefore, they were analyzed as one. Error bars represent standard error of three independent replicates when available. See also Figure S3 and Tables S1, S3, and S4. Figure 3 . Bromodomain Binding to H4-Acetylated Tail Enhances H2A.Z Acetylation (A) Heatmap showing p300 BD binding preference for H2A.Z and H4 peptides from histone peptide microarray analysis. Scalebar shows the color key to the relative intensity, normalized to the peptide with the highest raw signal (H4K5acK8acK12acK16ac). Data are represented as mean normalized signal (n = 6). Array 1 was used for this experiment. The complete list of peptides included in the histone peptide microarray is in Table S1 . di-, tri-, and tetra-acetylation states. Thus, we considered H4K5ac ChIP-seq data as reporting on H4 N-terminal tail poly-acetylation (referred to herein as H4ac), a signature consistent with the binding activity of p300 BD ( Figure 3A ).
We first investigated the co-occurrence of H2A.Zac and H4ac ChIP-seq peaks genome-wide and found a significant overlap, with 51.8% of H2A.Zac peaks coinciding with H4ac ( Figure 4A ). To consider the predicted functional properties, we used ChromHMM to demarcate six different genomic regulatory regions based on the information from six chromatin marks ( Figure S5A and Table  S2 ). We found that H4ac had a similar functional distribution pattern as H2A.Zac , where it was significantly enriched at promoters and enhancers and depleted at polycomb and transcribed regions ( Figure S5B ). To address whether the epigenetic context impacts the coexistence of H2A.Zac and H4ac, we also performed ChromHMM analysis of the overlapping marked peaks (23,904 regions, called common peaks) and unique marked peaks for H2A.Zac or H4ac (20,876 and 15,460 regions, called H2A.Zac-or H4ac-unique peaks, respectively) ( Figure 4B ). We found that the common peaks were most significantly located at active promoters: 51.64% of the common peaks ( Figure 4B, upper panel) and 68.74% of all active promoters ( Figure 4C ). In contrast, the uniquely marked regions were more prevalent at enhancers ( Figure 4B , middle and bottom panels), where most of the H2A.Zac-unique peaks occurred at active enhancer regions ( Figure 4B, middle panel) , whereas H4ac-unique peaks were mostly enriched at poised enhancers ( Figure 4B, bottom panel) . However, at distal regulatory regions, we observed that both common and unique regions were present in different proportions ( Figure 4D) , suggesting a dynamic interplay of these two marks.
Epigenetic Characteristics of Enhancers with Differential Distribution of H2A.Zac and H4ac
In order to further define the patterns of H2A.Zac-and H4ac-marked nucleosomes at enhancers, we examined different epigenetic features at these regions, including H2A.Z, p300, and H3K27ac, DNA methylation, and chromatin accessibility (Table S2 ). ChIP-seq data was split by H2A.Zac and H4ac signatures and ordered by H2A.Zac intensity at both poised and active enhancers ( Figure 4E ). Notably, we found that enhancers lacking H2A.Zac were not enriched for total H2A.Z, suggesting that enhancers with an H4ac-unique signature are also void of H2A.Z. Second, in agreement with a p300 BD-mediated recruitment mechanism proposed by this study and others (Conery et al., 2016; Manning et al., 2001 ), p300 showed differential occupancy between groups at both active and poised enhancers; in particular, the group lacking H4ac showed less p300 occupancy. Finally, H3K27ac, a histone PTM signature characteristic of active enhancers, did not show differential distribution between the groups, although H3K27ac intensity correlated with H2A.Zac signal. These data suggest a common pattern of acetylation of H3K27ac and H2A.Zac that may be established by p300.
We next used Nucleosome Occupancy and Methylation sequencing (NOMe-seq) data to study DNA methylation and chromatin accessibility at these enhancer sites (Kelly et al., 2012) . We found that H2A.Zac-unique enhancers had less DNA methylation and were more accessible than the average of all active and poised enhancers. In contrast, H4ac-unique active and poised enhancers had more methylation and were less accessible ( Figure 4F ). Enhancers carrying both H2A.Zac and H4ac had similar levels of DNA methylation and accessibility as the average enhancers. In summary, we found that enhancers with differential H2A.Zac and H4ac signatures are associated with distinct epigenetic features ( Figure 6B) . (0, 2, 4, 8, 16, 32, and 64 min) . The right plot shows the density quantificatification of H2B/H3, H2A.Z, and H4 acetylated bands over time. (D) Heatmap showing p300 BD binding preference for H2A.Z and H4 peptides in the presence or absence of CBP30 inhibitor from histone peptide microarray analysis. DMSO was used as vehicle control. Scalebar shows the color key to the relative intensity, normalized to the IgG positive control of each array. Data are represented as mean normalized signal (n = 6). Array 1 was used for this experiment. The complete list of peptides included in the histone peptide microarray is in Table S1 . (E) H 3 fluorography (top) and Coomassie staining (bottom) of canonical, H2A.Z-1 and H4K5acK8acK12acK16ac modified canonical nucleosomes incubated with p300 in the presence of CBP30 or DMSO as indicated. (F) Western blot analysis of HCT116 cells treated with CBP30 for 24 h at increasing concentrations (1, 2.5, 5, and 10 mM). Representative image of at least two biological replicates (top) and densitometry quantification represented in logarithmic scale (bottom). Protein abundance was calculated relative to DMSO control, and data are represented as mean and SD (n = 2). Student's t-test was performed to compare each condition to DMSO. *p value<0.05, **p value<0.01, ***p value<0.001. See also Figure S4 and Table S1 .
Acetylation Dynamics between H2A.Z and H4 at Enhancers Is Associated with Transcription Elongation
Chromatin accessibility and DNA methylation are indicative of enhancer activity (Valdes-Mora et al., 2017). To characterize the functional status of each enhancer H4/H2A.Z acetylation signature, we examined RNA polymerase II (RNApolII) recruitment and enhancer RNA (eRNA) production (Kim et al., 2010) as additional markers of enhancer function (Table S2 ). Figure 5A shows RNApolII ChIP-seq signal and Global Run-on sequencing (GRO-seq) data across active and poised enhancers. eRNA production is measured as the bidirectional RNA expression detected by GRO-seq around the DNAseI midpoint. Despite no major differences between H2A.Zac/H4ac signatures in eRNA production and the presence of RNAPolII flanking DNA-seI sites, we did reveal evidence of differential transcription across the entire 4kb region plotted ( Figure 5A ). H2A.Zac-unique enhancers had less regional transcriptional activity than the other two groups (common and H4ac-unique) in both active and poised enhancers.
To confirm that the observed transcription signal at expanded enhancers was due to transcription elongation, we grouped the enhancers according to their location inside or outside genes and compared their proportion with the rest of the enhancers ( Figure 5B) . A higher proportion of H4ac-unique enhancers were located at intragenic regions. H2A.Zac-unique active enhancers did not show differential localisation, whereas H2A.Zac-unique poised enhancers showed a higher presence at intergenic regions ( Figure 5B ). Common enhancers had similar inter/intragenic distribution to all detectable active and poised enhancers. We also found that genes with H2A.Zac-unique enhancers had significantly lower transcription compared with all genes containing either active or poised enhancers, whereas H4ac-unique enhancers were mostly present at highly expressed genes ( Figure 5C ). Moreover, the nascent RNA profiles measured by GROseq at intragenic enhancers validated the gene expression pattern (Figures 5D and S5C) .
Taken together, these results demonstrate a particular H2A.Zac and H4ac pattern, or enhancer code, that correlates with their genomic localization (inter or intragenic), regional transcriptional activity, chromatin features (p300, chromatin accessibility), and DNA methylation ( Figure 6B ).
DISCUSSION
A key step to understanding histone PTM function is the characterization of the enzymes and effector proteins that write, erase, and read these marks. Although much progress has been made identifying the core histone PTM modifiers (Voss and Thomas, 2018) , the specific enzymes that target histone variants PTMs have not been well studied. In particular, the KATs responsible for acetylation of H2A.Z in mammals are still unresolved. Here, we report that in addition to Tip60, p300 is able to acetylate the histone variant H2A.Z and that p300-dependent H2A.Z acetylation is enhanced through BD recognition of H4ac.
Unlike Tip60, p300 has not been described to interact with H2A.Z (Choi et al., 2009; Link et al., 2018; Obri et al., 2014; Vardabasso et al., 2015) , as it potentially follows a hit-and-run kinetic mechanism (Liu et al., 2008) . Tip60, however, has been described as the KAT candidate responsible for acetylation of H2A.Z (Corujo and Buschbeck, 2018; Giaimo et al., 2019; Sevilla and Binda, 2014) . Tip60 is part of a larger complex, involved in H2A.Z histone exchange (Altaf et al., 2010; Cai et al., 2003; Keogh et al., 2006; Kusch (F) Nucleosome occupancy and methylation sequencing (NOMe-seq) plots representing the average DNA methylation (0-1) and chromatin accessibility (1 minus GpC methylation ratio) ratios across active (left hand side) and poised enhancers (right hand side) divided into the same three groups than panel (B) . The average of all active and poised enhancers is also included. See also Figure S5 and Table S2 . et al., 2004) , which makes it difficult to assess whether Tip60 alone is able to acetylate H2A.Z. In fact, our in vitro results show that Tip60 acetylates peptide and nucleosomal H4 but does not efficiently acetylate H2A.Z. However, we and others (Dalvai et al., 2012; Li et al., 2019) found that genetic inhibition of Tip60 decreases H2A.Zac levels, suggesting that Tip60, in its cellular context, facilitates H2A.Z acetylation. Of note, complete knockout of Tip60 does not abolish H2A.Zac (Li et al., 2019) , and other reports found that acetylation of H2A.Z was independent of Tip60 at some locus-specific promoter Semer et al., 2019) , supporting our finding that p300/CBP is also required for the acetylation of H2A.Z. Based on our new data, we propose a model whereby acetylation of H2A.Z is the result of a sequential cascade initiated by Tip60-mediated acetylation of H4, leading to the recruitment of p300 via its BD to acetylate H2A.Z. Alternatively, Tip60 and p300/CBP may acetylate H2A.Z directly through independent pathways ( Figure 6A ).
We provide biochemical evidence that the presence of acetylated H4 in the nucleosome can have impact on p300-mediated acetylation of H2A.Z, suggesting that these two marks are co-localized. It was previously shown by immunoprecipitation that H2A.Z nucleosomes are enriched for H4ac (Draker et al., 2012; Myers et al., 2006) . Based on our analysis of ChIP-seq data, we found that H2A.Zac and H4ac cooccurred predominantly at promoters and enhancers. However, at a third of all enhancers, these marks did not co-occur. After dissecting the epigenetic features of each sub-group of enhancers, we propose a dynamic mechanism for enhancer activation through three states of activity ( Figure 6B) : poised, poised-active, and active. Each state has a preferential H4ac/H2A.Zac combination that would initiate from H4ac-marked nucleosomes at poised enhancers that enables the recruitment of p300 through its BD. This may trigger H2A.Z acetylation through p300 in a poised/active state and deacetylation of H4 in a fully enhancer-activated state.
Additionally, we also find different transcriptional features of each state. H2A.Zac-unique enhancers are enriched at intergenic regions or within lowly expressed genes; conversely, H4ac-unique enhancers are present in intragenic regions and are associated with highly transcribed genes, whereas common enhancers are characterized by an intermediate state regarding transcription elongation. The lack of H2A.Zac at intragenic enhancers of highly expressed genes could be due to the previously reported active removal of H2A.Z at gene bodies during transcription elongation (Hardy et al., 2009; Lashgari et al., 2017) . It is therefore interesting to note that H2A.Zac-marked active enhancers are not present within the gene they activate, as transcription elongation of the gene would remove H2A.Z from the enhancer, suggesting that H2A.Zac enhancers are likely acting as trans-regulatory elements. In this regard, a recent study showed that functionally active intragenic enhancers can attenuate transcription of the host gene (Cinghu et al., 2017) , supporting our observation.
In contrast, the lack of H4ac at H2A.Zac-unique enhancers is less clear. Genome-wide mapping of KATs and lysine deacetylases (KDACs) have shown that both enzyme families are targeted to active genes and correlate with transcription levels (Wang et al., 2009) , which suggests a high turnover rate of histone acetylation at highly transcribed genes compared with lowly transcribed genes or intergenic regions. Weinert et al. data reported a higher deacetylation rate of H4 compared with H2A.Z (Weinert et al., 2018) . We, therefore, propose that these different kinetics could partially explain the lack of H4ac at these H2A.Zac regions. However, we cannot rule out that p300 and Tip60 are able to acetylate H2A.Z without the presence of H4ac at these particular sites. Collectively, we demonstrate that p300/CBP, complementary to Tip60, are essential KATs for the acetylation of H2A.Z, answering the long-standing question of what enzymes are responsible for this important modification. We reveal a mechanism of histone PTM crosstalk and define an enhancer code based on the patterning of H4ac and H2A.Zac. Both p300 and H2A.Z have been implicated in many human cancers (reviewed in Iyer et al., 2004; Vardabasso et al., 2014) ; therefore, this study provides p300 as an additional target for H2A.Zac-based chromatin therapy in cancer. 
Limitations of the Study
In this study we demonstrate that p300-BD interaction with H4ac enhances H2A.Z acetylation using an inhibitor of p300 BD. However, we were not able to directly compare p300-mediated acetylation in a nucleosomal context with pre-installed H4ac/H2A.Z nucleosomes due to the technical difficulty in generating recombinant H4ac/H2A.Z combinatorial nucleosomes in vitro. Additionally, we found that H2A.Zac levels are reduced after inhibition of both Tip60 and p300, but we were unable in this study to determine if the mechanism that results in H2A.Zac involves a sequential cascade through H4ac or occurs through independent pathways. Future studies will focus on resolving the interplay and order of events that are associated with Tip60 and p300 in driving the acetylation of H2A.Z.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.10.053. Figure S1 . Extended data for in vitro assays and explanatory diagrams. Related to Figure 1. (A) p300 domain structure map and length information of the recombinant p300 enzymes used. (B) Coomassie staining of recombinant Tip60 and p300 catalytic domain used for the KAT assays. (C) In-solution H 3 -Acetyl-CoA (AcCoA) assays measuring Tip60 activity as a function of time on the un-acetylated H2A.Z peptide (amino acid 1-19, H2A.Z-1 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) ) and the tri-acetylated H2AZ at lysines 4, 7 and 11 (H2A.Z-1 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) K4acK7acK11ac). Same data as Figure 1B is shown but the scale of the y-axis has been adjusted to lower numbers to appreciate the discrete changes in H2A.Z acetylation. Data points are presented as counts per minute (cpm). Error bars represent the standard deviation from two measurements. (D) In-solution H 3 -AcCoA KAT assays measuring full length p300 activity on the listed histone peptide substrates after 30 minutes of H 3 -AcCoA incubation. Data points are presented as counts per minute (cpm). Error bars represent the standard deviation from two measurements. (E) Fluorescence assay measuring p300 activity on the listed histone peptide substrates after 15min incubation with Acetyl-CoA. Data points are presented as fluorescence units (FU). Error bars represent the standard deviation from two measurements. (F) Amino acid sequence of the isoforms H2A.Z-1 and H2A.Z-2 N-terminal peptides. Figure 3C shows the double band detected with the H2A.ZK7ac antibody by western blot imaging. For comparison, we also show images from total H2A.Z and H4. The signal intensity of two arrays was averaged and normalized to the peptide with the strongest signal in each array. Array 2 was used for those experiments See list of peptides in Supplemental Table 1 . N-terminus. (B) Heatmap showing p300 BD binding to all acetylated histone peptides on the peptide microarray. The scalebar shows the color key of the relative intensity normalized to the peptide with the highest signal (H4K5acK8acK12acK16ac). Data are represented as mean normalized signal (n=6) (C) Scatterplots showing histone peptide microarray raw signal of each peptide hybridized with p300 BD in the presence of CBP30 inhibitor or the vehicle control, DMSO (outset). Comparison of two independent microarray experiments for the p300 BD (inset). Data are represented as mean raw signal (n=6). We performed linear regression analysis derived from the average of 6 individual peptide spots printed by two different pins in two very different locations on the slide and r2 calculation shows the degree of similarity between two different subarrays. (D) Representative image of peptide arrays hybridized with p300 bromodomain in the presence of CBP30 inhibitor or the vehicle control, DMSO. White boxes mark peptides bound by p300 bromodomain in the vehicle control and yellow boxes demarcate positive controls. The different numbers display the peptides of interest for this study. The Array 1 was used for experiments from panel B, C, and D. A complete list of peptides included in the histone peptide microarray is in Supplemental Table 1 . Figure S5 . Extended data for genomic analysis. Related to Figure 4 and 5 (A) Heatmap of the ChromHMM state emissions from LNCaP cells. The x axis shows the different histone marks used for the partition of the genome in 9 chromatin states using the ChromHMM algorithm . The emission signal indicates the relative contribution of the histone mark in that state. Redundant states were merged into seven states and manually annotated by comparison to public ChromHMM states for HMEC cells . Table S2: Briefly, band densities were plotted using their Gels commands and area under the curve was quantified. Band densities of the protein of interest were divided by a loading control protein and further normalized to the control sample. Average and standard error of the mean were calculated for replicates using Prism 7 software and Student's t-test pairwise comparison was applied.
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RNA extraction and real time qPCR
Total RNA extraction was performed using TRIzol reagent (Life Technologies, #15596018) following manufacturer's instructions. 10µg of extracted RNA were treated with Turbo DNAfree kit (ThermoFisher Scientific, #AM1907) and complementary DNA (cDNA) generation was performed using SuperScript III Reverse Transcriptase (Invitrogen, #18080-044) and random hexamer primers (ThermoFisher Scientific #SO142) following manufacturer's instructions. 3µL of diluted cDNA(1:10) was added to 7µL of PCR master mix containing, 5µL of Power Sybr Green (ThermoFisher Scientific, #4367659), 1µL of each primer set (2µM). Quantitative real-time PCR (qRT-PCR) was performed using the ABI-PRISM 7900HT Sequence Detection System using the following conditions: 1) 50 o C for 2 min; 2) 95 o C for 10 min; 3) 40 cycles of 95 o C for 15 sec and 60 o C for 1 min. The data is represented as the fold change of mRNA gene expression normalized to the endogenous reference Gapdh and relative to the scramble condition. The list of all primer sequences used for this manuscript can be found in Supplemental Table 4 .
Data analysis:
ChIP-seq reads (see Supplemental Table 2 ) were mapped to the human genome (hg19) using Bowtie (version 1.0.1) (Langmead et al., 2009) , allowing up to three mismatches. Nonuniquely alignable reads were excluded. For H2A.Zac and H4K5ac, broad peaks were called using PeakRanger (version 1.16) (Feng et al., 2011) , peaks from replicates, when available, were combined by taking overlapping regions.
